{"entity":{"id":"nct06687681","kind":"trial","name":"Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas","aka":[],"tldr":"A phase 2 trial of NK cell therapy in glioma & glioblastoma, run by Marzieh Ebrahimi, now recruiting.","summary":"Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas is a phase 2 interventional study registered as NCT06687681 by Marzieh Ebrahimi, with 40 participants planned, started 2024-11-25 and due to reach its primary completion in 2025-11-25. Interventions recorded: NK cell therapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06687681","url":"https://clinicaltrials.gov/study/NCT06687681"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06687681","phase":"2","setting":"Efficacy of the Intrathecal Injection of Active Allogeneic Natural Killer Cells in Patients With High-grade Gliomas; A Multi-center Phase II Clinical Trial","sponsor":"Marzieh Ebrahimi","enrolled":40,"outcomes":[]},"route":"/trials/nct06687681/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}